to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Clinical trial NCT04301739 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT04301739
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-17
- Primary completion
- 2022-09-07
- Enrollment
- 522
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.